Otrera Medical is a preclinical stage pharmaceutical company developing treatments for unmet female sexual health needs.
In Greek mythology, Otrera was the first Queen of the Amazon.
Our Focus
Antidepressant-Induced Female Sexual Dysfunction
An efficacy signal—both preclinical & clinical—forms the basis for our patented treatment.
1 in 4 women in the U.S. are on antidepressants.
Half of women on antidepressants have arousal difficulty.
Over 15% of women stop taking their antidepressants because of negative sexual side effects.
Other Indications: Endometriosis & Dysmenorrhea
The Team
-
Dr. Harin Padma-Nathan, MD
Dr. Padma-Nathan, a prior Professor of Clinical Urology, USC was the lead American principal investigator for Viagra and oversaw the first ED trials with Cialis.
He is a co-founder of Vella Bioscience, and a co-inventor, with Dr. Frid, of Vella Pleasure Serum.
Dr. Padma-Nathan has published extensively, including two articles in the New England Journal of Medicine. Additionally, his research has been cited on the front pages of the New York Times, the Los Angeles Times, and the Sunday London Times Magazine.
.
-
Dr. Michael Frid, PhD
Dr. Frid is a formulation chemist with expertise in drug development, from late discovery to early clinical. He has more than 15 years of experience in pharmaceutical development, including discovery, lead optimization, lead selection and proof of concept in humans.
Dr. Frid holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and a BS in chemistry cum laude from New York University.
He is a co-founder of Vella Bioscience, and a co-inventor, with Dr. Padma-Nathan, of Vella Pleasure Serum.
-
Dr. Janice Lipsky, PhD
Dr. Lipsky is an accomplished pharmaceutical marketing executive with over 25 years of experience.
Dr. Lipsky spent twelve years at Pfizer, during which time she spent several years heading the US Viagra Marketing Team, helping drive the brand to $1 billion and staving off competitors.
Other successful launches and acquisitions include Medicis, Ulthera, Merz.
A Serendipitous Discovery
A 23-year-old woman mistakenly entered a sexual wellness trial at Vella Bioscience. She reported that since starting her SSRI 3 years ago, she had become anorgasmic.
She became orgasmic each time she used our topical prototype.
A pilot trial in 5 additional women with SSRI-related anorgasmia demonstrated that 5 out of 6 women were able to reestablish their pre-SSRI orgasm and with 75-100% quality (e.g., ease, intensity).
“Within two weeks of taking the prescribed SSRI, I suddenly lost my ability to orgasm, which had previously never been a problem. Without fail, every single time I use the product, I am able to reach orgasm with pleasure and ease. It has allowed me to take care of my mental health and remain on the medication needed, without sacrificing my sexual wellness and pleasure.”
— Study Participant
Capital Raise
Pre-Seed
We are raising $1M.
These funds will allow us to reach our first milestone, the submission to the FDA of our preclinical IND package for a treatment for antidepressant-induced female sexual dysfunction.Email info@otreramedical.com if interested in learning more about this investment opportunity in women's sexual medicine.
We believe that a woman shouldn’t have to chose between her mental health & her sexual health.
Contact Us
info@otreramedical.comMansfield Bio-Incubator 241 Francis Avenue
Mansfield, MA 02048